Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy pens are pre-filled, once-weekly injection devices containing semaglutide, a GLP-1 receptor agonist licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. Each pen delivers a single dose subcutaneously — into the fatty tissue under the skin — and requires a valid prescription following clinical assessment. Because semaglutide is a prescription-only medicine, a registered prescriber must assess your suitability before treatment can begin.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy pens live in the fridge between 2 and 8 °C. Before you inject, take the pen out and let it sit at room temperature for a few minutes, a cold injection is more likely to sting. Check the liquid through the viewing window: it should be clear or faintly opalescent, colourless to pale yellow, with no particles floating in it. If it looks cloudy or discoloured, do not use that pen and contact your prescriber.
Choose one consistent day of the week for your injection, many people tie it to something fixed, like a Sunday morning routine. Wash your hands thoroughly first. You'll want a clean alcohol swab to prepare the injection site; single-use swabs are a practical way to keep a supply to hand. Rotate your injection site each week: abdomen (at least 5 cm from the navel), outer thigh, or upper arm. Rotating matters because using the same spot repeatedly can cause tissue changes that affect how well the medicine absorbs.
For a detailed visual walkthrough of the injection technique, our Wegovy pen how-to guide covers each step with practical notes from the clinical team. Your Patient Information Leaflet (included with every pen) is the definitive reference and should be read before your first injection.
Remove the pen cap. Do not attach a needle, Wegovy pens have a built-in, covered needle mechanism; there is nothing to screw on or prime. Pinch the skin lightly if you have less subcutaneous tissue in the chosen area. Hold the pen against the skin at a 90-degree angle, press down firmly until you hear or feel a click, and hold the pen in place for the count of five seconds before removing it. The needle retracts automatically.
A small amount of resistance or a faint prick is normal. Bruising occasionally appears at the site, particularly early in treatment, it usually fades within a day or two and is not a sign that anything went wrong. Do not rub the area after injecting.
Used pens contain an exposed needle mechanism and count as sharps waste. They must not go in household recycling or your general bin. A dedicated sharps container is the safe way to dispose of them, and your local pharmacy or GP surgery can usually advise on collection arrangements in your area.
A question our prescribers hear most weeks: "Can I stay on the lower dose longer if it's working?" The answer is yes) with their guidance. The titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, up to 2.4 mg, moving roughly every four weeks) is designed first to reduce side effects, then to bring you to a therapeutic level. Jumping ahead increases the risk of nausea and vomiting without meaningfully speeding up results. Staying behind for too long may limit effectiveness. That balance is a clinical judgement.
The higher 7.2 mg dose (approved by the MHRA in April 2026, initially supplied as three standard 2.4 mg pens per week, now also available as a dedicated four-pen pack, and now also available as a dedicated single-dose pen) is not automatically the destination for every patient. It is appropriate only for certain adults with a BMI of 30 or above, and the decision sits firmly with your prescriber. You can read more about how individual Wegovy pens are structured, or explore the mechanism behind how semaglutide works in the body.
For context on the evidence behind this treatment, the STEP 1 trial (published in the New England Journal of Medicine) reported around 15% average weight reduction over 68 weeks at the 2.4 mg maintenance dose. Clinical trials involve specific populations and controlled conditions; individual results vary, and a prescriber's oversight is part of what makes outcomes sustainable.
The most common side effects with Wegovy pens are gastrointestinal: nausea, loose stools, constipation, burping, and indigestion are reported most often, particularly when starting out or moving up a dose. They tend to be at their worst in the first week or two after a change and settle as your body adjusts. Eating smaller portions, slowing down at mealtimes, and staying well hydrated all help.
Headache, tiredness and injection-site reactions (redness, itching) are also reported. More serious but less common effects include gallbladder problems and acute pancreatitis. The NHS semaglutide medicine page lists the full side-effect profile with clear guidance on urgency. Get medical help promptly if you develop severe stomach pain that radiates through to your back (with or without vomiting) as this can be a sign of pancreatitis requiring assessment.
If you are using oral contraceptives, speak to your prescriber about whether any changes to your contraception are advisable while on semaglutide. Pregnancy, breastfeeding and actively trying to conceive are all situations where this medicine is not recommended; under-18s are not licensed for treatment. Missed doses, mid-treatment breaks or any side effect that concerns you should be discussed with your prescriber, or with our clinical team through the aftercare contact page if you're a nume patient. You can also report suspected side effects directly to the MHRA at the Yellow Card scheme.
Curious about how Wegovy pens in the UK compare with the wider semaglutide landscape, including Ozempic? If you want to understand how Ozempic fits into the picture as a weight loss injection, including where it sits relative to Wegovy, that page explains the key distinctions. If you want to understand the full range of semaglutide pens available, including how they differ by dose and device, explains the licensing differences plainly. If you're considering whether Wegovy or tirzepatide might be the better fit for you, the weight-loss treatment overview sets out what's licensed and available. When you're ready to find out whether you're clinically suitable, check your eligibility with our prescribers, the consultation is free, and a real clinician reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.